#GEJcancer
LightNews LightNews
oncodaily.bsky.social
Envafolimab Receives FDA Orphan Drug Designation for Gastric and Gastroesophageal Junction Cancer

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #GastricCancer #GEJCancer #FDA
Envafolimab Receives FDA Orphan Drug Designation for Gastric and Gastroesophageal Junction Cancer - OncoDaily
Envafolimab, the world’s first subcutaneous PD-L1 inhibitor, receives FDA Orphan Drug Designation for gastric and gastroesophageal junction cancer, highlighting a novel, patient-friendly immunotherapy...
oncodaily.com
December 23, 2025 at 10:10 PM
dengyuemedicine.bsky.social
China’s NMPA Approves Zolbetuximab for Injection

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#Zolbetuximab
#Wiluyi
#CLDN182
#GastricCancer
#GEJCancer
#Astellas
#NMPAApproval
#Oncology
#TargetedTherapy
#MonoclonalAntibody
November 14, 2025 at 9:46 AM
oncodaily.bsky.social
FGFR2-IIIc: Prognostic Biomarker and Resistance Mechanism in Gastric and GEJ Cancer

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #FGFR2-IIIc #GastricCancer #GEJCancer
FGFR2-IIIc: Prognostic Biomarker and Resistance Mechanism in Gastric and GEJ Cancer - OncoDaily
FGFR2-IIIc: Prognostic Biomarker and Resistance Mechanism in Gastric and GEJ Cancer / cancer, cancer awareness, cancer care, Cancer research, cancer
oncodaily.com
November 9, 2025 at 9:08 PM
myesmo.bsky.social
#ESMO25: Phase III FORTITUDE-101 #ClinicalTrial reports improved short-term survival with first-in-class FGFR2b inhibitor bemarituzumab added to chemotherapy to treat FGFR2b-overexpressing #Gastric or #GEJCancer.
More in the #ESMODailyReporter ➡️ https://ow.ly/C2MU50Xf08l
October 20, 2025 at 4:02 PM
4040rec.bsky.social
#Astellas #pancreaticcancer #Vyloy #zolbetuximab #claudin182targetingcancerdrug #GLEAMstudy #metastaticpancreaticadenocarcinoma #GLEAMtrial #pancreaticcancerresearch #claudin182targetedtherapy #CLDN182testing #GanymedPharma #ESMO #GEJcancer #biopharma
zurl.co/DtTYd
Astellas suffers pancreatic cancer failure with Vyloy
Astellas' effort to expand the reach of its first-in-class claudin 18.2 drug Vyloy into pancreatic cancer has had a major setback.
zurl.co
October 16, 2025 at 10:17 AM
oncodaily.bsky.social
DANTE Trial: Phase III Recruitment Completed in Gastric and GEJ Cancer

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #DANTE #IO #GastricCancer #GEJCancer
DANTE Trial: Phase III Recruitment in Gastric and GEJ Cancer
The DANTE trial completes Phase III recruitment, testing atezolizumabF+LOT in resectable gastric and GEJ cancer with a biomarker-driven design.
oncodaily.com
August 20, 2025 at 12:49 AM
onclive.bsky.social
ATG-022 Earns Breakthrough Therapy Designation in China for Advanced Gastric/GEJ Adenocarcinoma
#GastricCancer #stcsm #GEJcancer
www.onclive.com/view/atg-022...
ATG-022 Earns Breakthrough Therapy Designation in China for Advanced Gastric/GEJ Adenocarcinoma
The NMPA has granted breakthrough therapy designation to ATG-022 for previously treated gastric and gastroesophageal junction adenocarcinoma.
www.onclive.com
August 19, 2025 at 3:23 PM
greatdebates.bsky.social
GEJ cancer treatment planning isn’t always clear-cut.

At #GDST, Drs. Biachi and Uboha debate neoadjuvant vs adjuvant strategies—downstaging, recurrence risk, and the role of ctDNA in refining decisions.

Learn more: www.hmpglobalevents.com/gdst

#GEJcancer #Oncology #CancerResearch
July 7, 2025 at 8:10 PM
oncodaily.bsky.social
FORTITUDE-101 Study Updates 2025: Bemarituzumab Plus mFOLFOX6 in FGFR2b-Positive Gastric and GEJ Cancer

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #FORTITUDE101 #Bemarituzumab #mFOLFOX6 #GEJCancer #GastricCancer
FORTITUDE-101 Study Updates 2025: Bemarituzumab Plus mFOLFOX6 in FGFR2b-Positive Gastric and GEJ Cancer - OncoDaily
FORTITUDE-101 Study shows that Bemarituzumab Plus mFOLFOX6 improves OS in patients with FGFR2b-Positive Gastric and GEJ Cancer.
oncodaily.com
July 3, 2025 at 10:07 PM
msklibrary.bsky.social
Featured today by @MSKLibrary: Genomic Landscape of Adenocarcinomas Across the Gastroesophageal Junction: Moving on From the Siewert Classification dx.doi.org/10.1097/SLA....

#GEJGenomics #GastroesophagealCancer #PrecisionOncology #CancerGenomics
#Adenocarcinoma #BeyondSiewert #GEJCancer
Genomic Landscape of Adenocarcinomas Across the... : Annals of Surgery
rs, whereas tumors with an epicenter >2 cm into the cardia be staged and treated as gastric cancers. To date, however, few studies have compared the genomic profiles of the 3 Siewert classification gr...
dx.doi.org
June 11, 2025 at 4:42 PM
oncologynurseadv.bsky.social
Atezolizumab may improve upon perioperative treatment with trastuzumab and chemotherapy in patients with HER2-positive, locally advanced, resectable gastric or #GEJcancer, according to researchers. Reported in @jama.com journal Oncology and @cancertherapyadv.bsky.social.

bit.ly/3FxyI1Z
Atezolizumab May Provide Added Benefit in HER2+ Gastric/GEJ Cancer - Oncology Nurse Advisor
Atezolizumab may improve upon perioperative treatment with trastuzumab and chemotherapy in HER2+, locally advanced, resectable gastric or GEJ cancer, researchers say.
bit.ly
June 10, 2025 at 6:38 PM
oncodaily.bsky.social
New Paper Alert: NO LIMIT Trial. First-Line Nivolumab Plus Low-Dose Ipilimumab in MSI-High Advanced Gastric and GEJ Cancer

oncodaily.com/opinion/nivo...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NOLIMIT #Nivolumab #Ipilimumab #GEJCancer #GastricCancer
No Limit trial: Results of Nivolumab+Ipilmumab in MSI-H GC
Explore NO LIMIT trial's response rate with nivolumab plus low-dose ipilimumab in MSI-H advanced gastric cancer, showing durable clinical benefit.
oncodaily.com
May 19, 2025 at 8:18 PM